Efavirenz/Tenofovir/Emtricitabine (Atripla)

Overview | News | Research

Overview

Atripla (March/April 2012)
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
Prescribing Information for Efavirenz/Tenofovir/FTC (Atripla) (PDF) (September 2011)
From Bristol-Myers Squibb Company and Gilead Sciences, Inc.
Approval of Atripla (July 12, 2006)
From U.S. Food and Drug Administration

News

Changes to Label for Atripla (Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate) Tablets (April 18, 2013)
From U.S. Food and Drug Administration
Antiretroviral Rounds: Resistance on Two Fronts (November 2, 2012)
From Journal Watch
Switching From Atripla to Complera (January/February 2012)
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
Complera and Atripla News (January/February 2012)
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
Gilead Raises Prices of HIV Drugs, AHF Speaks Out Against Price Hike (April 4, 2011)
In Bloomberg Businessweek
Atripla's Co-Pay Program Now Saves More Money (September/October 2010)
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
The Once and Future King: What Will Replace Atripla Atop the First-Line HIV Treatment Realm? (Feb. 19, 2010; 3:39 p.m. Pacific Time)
A blog entry from CROI 2010 by Gerald Pierone Jr., M.D.
In The 17th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
Atripla Label Update Reflects New Efficacy, Safety and Resistance Data in Treatment Experienced Patients (January 7, 2010)
From U.S. Food and Drug Administration
Australia: New HIV Drug Added to Taxpayer-Subsidized List (January 4, 2010)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
Approval for Once-A-Day HIV Pill (December 17, 2007)
In BBC News Online, from BBC News

VIEW ALL ARTICLES

Research

Sustiva, Atripla Tied to Neurologic Toxicity (November/December 2012)
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
20% People Switch Atripla Due to Efavirenz Side Effects: Late Switches Are Common (May/June 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
Gilead's Quad Single Tablet Regimen for HIV Non-Inferior to Atripla in Pivotal Phase 3 Study (March 7, 2012)
Quad currently under review for marketing approval by U.S. and European regulatory agencies.
From Gilead Sciences, Inc.
A Truly Bizarre "Systematic" Review: A Blog Entry by Paul Sax, M.D. (February 26, 2012)
A surprising "systematic" review of Atripla research from Cochrane Summaries seems to leave out an awful lot of the system.
From Journal Watch
Hospital Rate Lower With Atripla Than Other Combos in Medicaid Patients (September 21, 2011)
From National AIDS Treatment Advocacy Project
Switching from Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Single Tablet Regimen (STR) to Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF) STR in Virologically Suppressed, HIV-1 Infected Subjects (September 21, 2011)
From National AIDS Treatment Advocacy Project
Switching From Atripla to Complera Safe and Effective in 12-Week Study (September 21, 2011)
From National AIDS Treatment Advocacy Project
Rate of Stopping Atripla for Side Effects Steady Through 96 Weeks in London Cohort (September 21, 2011)
From National AIDS Treatment Advocacy Project
A Fifth of Patients Discontinue Atripla Within a Year, CNS Side-Effects the Main Reason (September 19, 2011)
From aidsmap.com
ICAAC HIV Poster Roundup #1: Clinically Relevant Findings (September 19, 2011)
In The 51st Interscience Conference on Antimicrobial Agents and Chemotherapy, from TheBodyPRO.com

VIEW ALL ARTICLES

MOST VIEWED ARTICLES

	HIV Management Today: Mental Health & HIV, the Uncharted Territory
	10 Top Studies Whose Impact Will Last Well Beyond CROI 2013
	CROI 2013: Women's Issues in HIV Research (Video)
	Danish Study Targets HIV Reservoir, in Latest Search for HIV Cure
	PrEP Failures and Successes: One Study Whose Impact Will Last Well Beyond CROI 2013
	HIV Opportunistic Infection Guidelines Updated

More Most Viewed Articles

TheBodyPRO.com is a service of Remedy Health Media, LLC, 500 5th Avenue, 19th Floor, New York, NY 10110. TheBodyPRO.com and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of TheBodyPRO.com's homepage, topic pages, page designs and HTML code. General Disclaimer: TheBodyPRO.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBodyPRO.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.